146 related articles for article (PubMed ID: 8722423)
1. Can preirradiation enhance tumor uptake of radiolabeled pharmaceuticals? Experimental data in a mouse neuroblastoma xenograft system.
Sautter-Bihl ML; Bihl H
Recent Results Cancer Res; 1996; 141():123-35. PubMed ID: 8722423
[No Abstract] [Full Text] [Related]
2. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
3. Therapeutic use of I-131-MIBG in nude mice hosting human neuroblastoma xenografts.
Senekowitsch R; Laubenbacher C; Möllenstädt S; Kriegel H; Pabst HW
Strahlenther Onkol; 1989 Jul; 165(7):566-8. PubMed ID: 2749502
[No Abstract] [Full Text] [Related]
4. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
6. Systemic radiotherapy with monoclonal antibodies. An experimental study with human neuroblastoma xenografts in nude mice.
Sautter-Bihl ML; Matzku S; Bihl H
Strahlenther Onkol; 1993 Jul; 169(7):431-7. PubMed ID: 8342117
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations.
Sautter-Bihl ML; Herbold G; Bihl H
Recent Results Cancer Res; 1996; 141():67-75. PubMed ID: 8722420
[No Abstract] [Full Text] [Related]
8. Higher efficiency of 131I-labeled anti-carcinoembryonic antigen-monoclonal antibody F(ab')2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice.
Buchegger F; Mach JP; Folli S; Delaloye B; Bischof-Delaloye A; Pèlegrin A
Recent Results Cancer Res; 1996; 141():19-35. PubMed ID: 8722418
[No Abstract] [Full Text] [Related]
9. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2.
Yamamoto A; Sawada T; Yamashita Y; Nishihara T; Ho JJ; Kim Y; Chung KH
Oncol Rep; 1999; 6(1):179-84. PubMed ID: 9864424
[TBL] [Abstract][Full Text] [Related]
11. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
Flower MA; Fielding SL
Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE
Br J Radiol; 1995 Nov; 68(815):1263. PubMed ID: 8542240
[No Abstract] [Full Text] [Related]
13. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
Sautter-Bihl ML; Wessely R; Bihl H
Strahlenther Onkol; 1993 Oct; 169(10):595-600. PubMed ID: 8235984
[TBL] [Abstract][Full Text] [Related]
14. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
15. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160
[No Abstract] [Full Text] [Related]
17. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
18. The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain.
Miyamoto CT; Brady LW; Rackover MA; Emrich J; Class R; Bender H; Micaily B; Steplewski Z
Recent Results Cancer Res; 1996; 141():183-92. PubMed ID: 8722428
[No Abstract] [Full Text] [Related]
19. Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates.
Kemshead JT; Hopkins KI; Chandler CL
Recent Results Cancer Res; 1996; 141():145-58. PubMed ID: 8722425
[No Abstract] [Full Text] [Related]
20. Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts.
Kinuya S; Yokoyama K; Hiramatsu T; Tega H; Tanaka K; Konishi S; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
Cancer Lett; 1999 Jun; 140(1-2):209-18. PubMed ID: 10403561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
